A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02773030 |
|
Recruitment Status :
Recruiting
First Posted : May 16, 2016
Last Update Posted : October 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Multiple Myeloma | Drug: CC-220 Drug: Dexamethasone Drug: Daratumumab - 16mg/kg Drug: Bortezomib (BTZ) Drug: Carfilzomib Drug: Daratumumab- 1800mg | Phase 1 Phase 2 |
Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has been determined to be safe. Progressive disease must be confirmed in accordance with international myeloma working group (IMWG) criteria.
The starting dose of DEX will be 40 mg for subjects who are ≤75 years of age and 20 mg for subjects who are >75 years of age, given once weekly. This treatment will continue until PD, unacceptable toxicity or the subject withdraws consent.
For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose level -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21 days of a 28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of CC-220, dose level 1, is one dose level below the maximum dose for Cohort B that has been determined to be safe by the dose escalation committee (DEC) at the start of enrollment for both cohorts. For Cohort E in addition to CC-220 and DEX, daratumumab will be administered intravenously (IV) at a 16mg/kg dose. For Cohort F in addition to CC-220 and DEX, bortezomib will be administered subcutaneous (SC) at a 1.3mg/m2 dose.
All subjects with a minimal response (MR) or better who discontinue study treatment in Part 1 or Part 2 of the study for a reason other than PD or withdrawal of consent from the study will be followed for response assessment every 28 days (every 21 days for Cohort F) until PD.
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.
The initiation of Part 2 will begin when the RP2D is established in Part 1 in either Cohort A or Cohort B. Either cohort may begin once the RP2D is determined for each cohort independently during Part 1. All expansion decisions will be determined by the DEC after review of all safety, PK, biomarker and preliminary efficacy data, as applicable. During Part 2, the Independent Expert Reviewer will review safety data and any other data deemed relevant so that subject safety is ensured.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 464 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma |
| Actual Study Start Date : | October 14, 2016 |
| Estimated Primary Completion Date : | June 9, 2021 |
| Estimated Study Completion Date : | May 10, 2027 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort A: CC-220 Monotherapy - Part 1
Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide |
Experimental: Cohort B: CC-220 in combination with Dexamethasone - Part 1
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron |
Experimental: Cohort D: CC-220 in combination with Dexamethasone - Part 2
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron |
Experimental: Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1
Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Daratumumab - 16mg/kg Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Other Name: Darzalex Drug: Daratumumab- 1800mg Daratumumab (DARA) 1800 mg by subcutaneous injection on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
Other Name: Darzalex Faspro |
Experimental: Cohort F: CC-220 with DEX and bortezomib - Part 1
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Bortezomib (BTZ) Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Other Name: Velcade |
Experimental: Cohort G1-CC-220 in combination with CFZ and DEX -Part 1
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Carfilzomib Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.
Other Name: Kyprolis |
Experimental: Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Carfilzomib Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.
Other Name: Kyprolis |
Experimental: CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron |
Experimental: CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Bortezomib (BTZ) Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Other Name: Velcade |
Experimental: CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2
|
Drug: CC-220
CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
Other Name: Iberdomide Drug: Dexamethasone Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
Other Name: Decadron Drug: Bortezomib (BTZ) Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
Other Name: Velcade |
- Establish maximum tolerated doses (MTDs) of CC-220 as monotherapy and in combination with other treatment [ Time Frame: Approximately 1 year ]Establish the maximum tolerated doses (MTDs) of CC-220 monotherapy, in combination with DEX, and in combination with DEX and daratumumab (CC-220Dd), in combination with DEX and bortezomib (CC-220Vd), and in combination with DEX and carfilzomib (CC-220Kd)
- Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment [ Time Frame: Approximately 1 year ]RP2D is defined as the dose selected for phase 2 based on safety, pharmacokinetics and biomarker data from phase 1 of the study.
- Overall response rate (ORR) of CC-220 in combination with DEX in Cohort D in Part 2 [ Time Frame: Approximately 3 years ]Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Kumar, 2011) in CC-220 in combination with DEX
- Adverse Events (AEs) [ Time Frame: Approximately 3 years ]Type, frequency, seriousness and severity of adverse events (AEs) (and AEs of special interest) and relationship of AEs to investigational product
- Overall response rate (ORR) [ Time Frame: Approximately 3 years ]Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better
- Time to Response (TTR) [ Time Frame: Approximately 3 years ]Is defined as the time from the first date of dosing of IP to the first date of documented response (partial response [PR] or greater).
- Duration of Response (DOR) [ Time Frame: Approximately 3 years ]Is defined as Time from the first documentation of response (PR or greater) to the first documentation of Progressive disease (PD)
- Pharmacokinetics -AUC 0-τ [ Time Frame: Approximately 1 year ]Area under the plasma concentration-time curve from time zero to tau, where tau is the dosing interval
- Pharmacokinetics -Cmax [ Time Frame: Approximately 1 year ]Maximum plasma concentration of drug
- Pharmacokinetics -Tmax [ Time Frame: Approximately 1 year ]Time to Maximum plasma concentration of drug
- Pharmacokinetics -t1/2 [ Time Frame: Approximately 1 year ]Terminal-phase elimination half life
- Pharmacokinetics -CLss/F [ Time Frame: Approximately 1 year ]Apparent total plasma clearance when dosed daily
- Pharmacokinetics -Vss/F [ Time Frame: Approximately 1 year ]Apparent total volume of distribution at steady state when dosed orally
- Progression-free Survival (PFS) [ Time Frame: Approximately 3 years ]Time from the first dose of investigational product (IP) to the first documentation of PD or death from any cause, whichever occurs first
- Overall Survival (OS) in Part 2 RRMM cohorts [ Time Frame: Approximately 3 years ]Time from first dose of IP to death due to any cause
- Very good partial response or better rate (VGPR) [ Time Frame: Approximately 4 years ]Tumor response, including progressive disease (PD) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria (Kumar, 2016) for subjects who achieved VGPR or better
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
1. All subjects in RRMM cohorts must have a documented diagnosis of Multiple Myeloma and have measurable disease defined as:
- M-protein (serum and/or urine protein electrophoresis (sPEP or uPEP)): sPEP ≥0.5 g/dL or uPEP ≥200 mg/24 hours and/or
-
Light chain Multiple Myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio 2. All subjects in RRMM cohorts must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy. Subjects who had CAR T therapy as their last myeloma therapy must have documented disease progression.
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 3. Subject must have documented diagnosis with previously untreated symptomatic MM as defined by the criteria below (Rajkumar, 2016): MM diagnostic criteria;
- Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary plasmacytoma
- Any one or more of the following myeloma defining events:
-
One or more of the following myeloma-related organ dysfunction (at least one of the following);
• [C] Calcium elevation (serum calcium > 0.25 mmol/L [> 1 mg/dL] higher than the upper limit of laboratory normal or > 2.75 mmol/L [> 11 mg/dL])
• [R] Renal insufficiency (serum creatinine > 2 mg/dl [> 177 μmol/L] or creatinine clearance < 40 ml/min)
- [A] Anemia (hemoglobin < 10 g/dl or > 2 g/dL below the lower limit of laboratory normal)
- [B] Bone lesions (lytic or osteopenic) one or more bone lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)/CT
-
One or more of the following biomarkers of malignancy:
- Clonal bone marrow plasma cell percentage* ≥ 60%
- Abnormal serum free light-chain (FLC) ratio ≥ 100 (involved kappa) or <0.01 (involved lambda) and involved FLC level must be ≥ 100 mg/L
- >1 focal lesion detected by magnetic resonance imaging (MRI) (at least 5 mm in size)
AND have measurable disease, as assessed by central laboratory, defined by any of the following:
- Immunoglobulin (Ig)G myeloma: serum M-protein level ≥ 1.0 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
- IgA, IgM, IgD, or IgE multiple myeloma: serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
- Light chain multiple myeloma without measurable disease in serum or urine: serum FLC ≥ 100 mg/L and abnormal kappa lambda (κ/λ) ratio 4. Subjects in Cohort J1 are not considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation due to:
- Age ≥65 years, OR
- In subjects <65 years: presence of important comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with autologous stem cell transplantation.
5. Subjects in Cohort J2 are considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation according to the institution's criteria based on age, medical history, cardiac and pulmonary status, overall health and condition, co-morbid condition(s), physical examination, and laboratory data.
Exclusion Criteria:
1. Subject has nonsecretory multiple myeloma 2. Subjects with Plasma Cell leukemia or amyloidosis 3. Any of the following laboratory abnormalities
• Absolute neutrophil count (ANC) <1,000/μL
• Platelet count < 75,000/μL for Part 1. For Part 2; platelet count < 75,000/μL for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; otherwise platelet count < 50,000/μL (transfusions are not permitted to achieve minimum platelet counts
• Corrected serum calcium >13.5 mg/dL (>3.4 mmol/L)
- Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)≥2.0 x upper limit of normal (ULN)
- Serum total bilirubin and alkaline phosphatase >1.5 x ULN
- Subjects with serious renal impairment creatinine clearance ([CrCl] <45 mL/min) or requiring dialysis would be excluded 4. Subjects with peripheral neuropathy ≥Grade 2
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02773030
| Contact: Associate Director Clinical Trial Disclosure | 1-888-260-1599 | clinicaltrialdisclosure@celgene.com |
Show 72 study locations
| Study Director: | April Sorrell-Taylor, MD | Celgene Corporation |
| Responsible Party: | Celgene |
| ClinicalTrials.gov Identifier: | NCT02773030 |
| Other Study ID Numbers: |
CC-220-MM-001 U1111-1182-9200 ( Registry Identifier: WHO ) 2016-000860-40 ( EudraCT Number ) |
| First Posted: | May 16, 2016 Key Record Dates |
| Last Update Posted: | October 19, 2020 |
| Last Verified: | October 2020 |
|
Multiple Myeloma Relapsed Refractory Pharmacokinetics Safety Efficacy |
CC-220 Relapsed and refractory multiple myeloma Dexamethasone Daratumumab Bortezomib |
|
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone |
Bortezomib Daratumumab Antibodies, Monoclonal Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Immunologic Factors |